Skip to search formSkip to main contentSkip to account menu

BIIB022

Known as: Anti-IGF-1R Recombinant Monoclonal Antibody BIIB022, BIIB-022 
A recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Phase I, dose-escalation study of BIIB022 (anti-IGF-1R antibody) in advanced solid tumors.
2612 Background: The IGF pathway is believed to play a key role in the pathogenesis of several tumors. BIIB022 is a human… 
2009
2009
Dyax and Biogen Idec Expand Drug Discovery Deal
Biogen Idec has expanded its agreement to discover additional antibody products using Dyax’s phage display drug discovery… 
2009
2009
1227 A phase 1, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in patients with relapsed or refractory solid tumours
2008
2008
BIIB022, a human antibody targeting human insulin-like growth factor-1 receptor (IGF-1R), enhances the anti-tumor activities of Tarceva in non-small cell lung carcinoma (NSCLC) and Rapamycin in…
4002 Antibodies to IGF-1R as inhibitors of PI3K/AKT survival pathway have shown evidence of objective responses in early clinical… 
2007
2007
BIIB022, a fully human nonglycosylated γ4P antibody targeting IGF-1R for cancer therapy
B210 Antibodies targeting human type I insulin-like growth factor receptor (IGF-1R) as inhibitors of tumor survival pathway have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)